We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Trial watch: Telomerase inhibitor shows promise in myeloproliferative disorders.
- Authors
Cully, Megan
- Abstract
The article discusses findings of Phase II trials on the potential of telomerase inhibitor imetelstat as treatment for thrombocythaemia and myelofibrosis in cancer patients. It notes that 21 percent of patients with myelofibrosis showed a partial or complete response to imetelstat therapy, while 89 percent of patients with thrombocythaemia showed complete hematological response to the treatment. It suggests that imetelstat could target the cause and not just the symptoms of the disease.
- Subjects
CLINICAL trials; MYELOPROLIFERATIVE neoplasms; TELOMERASE; ENZYME inhibitors; TARGETED drug delivery; ANIMALS; TRANSFERASES; VITAMIN B complex; PHARMACODYNAMICS; INDOLE compounds; VITAMIN therapy; THERAPEUTICS
- Publication
Nature Reviews Drug Discovery, 2015, Vol 14, Issue 11, p741
- ISSN
1474-1776
- Publication type
journal article
- DOI
10.1038/nrd4762